Literature DB >> 18540829

Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions.

Shinichiro Fuse1, Michael J Molloy, Edward J Usherwood.   

Abstract

Persistent viral infections present a significant threat to society, and treatment options for infected individuals are in urgent demand. During viral persistence, the balance between the virus and the host immune response is crucial. The immune system keeps the virus in check, and the virus counters by evading the immune response to avoid clearance, ultimately tipping the balance in favor of the virus and causing disease in many cases. Thus, efforts to tip the balance in favor of the host through immunotherapy holds promise for establishing control of viral replication. However, in most persistent viral infections, the continuous presence of the viral antigen renders virus-specific T cells to become dysfunctional. These differences can range from severe functional impairments in high-load persistent infections, to more subtle changes in infections with a lower virus burden. Recent work has shed light on immunoregulatory molecules or cytokines that affect viral persistence and/or T-cell function, and interventions that modulate these factors have led to effective viral control in experimental models. Exploitation of these experimental therapies may lead to treatments that would be of great clinical benefit to patients suffering from persistent virus infections, such as HIV, HBV, or HCV, or the herpesviruses CMV and EBV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540829     DOI: 10.1615/critrevimmunol.v28.i2.40

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  14 in total

1.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery.

Authors:  Shaobo Han; Ayuna Asoyan; Hannah Rabenstein; Naoko Nakano; Reinhard Obst
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

3.  Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus.

Authors:  Michael J Molloy; Weijun Zhang; Edward J Usherwood
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

4.  Intraocular levels of interleukin 17A (IL-17A) and IL-10 as respective determinant markers of toxoplasmosis and viral uveitis.

Authors:  Arnaud Sauer; Odile Villard; Catherine Creuzot-Garcher; Christophe Chiquet; Jean-Paul Berrod; Claude Speeg-Schatz; Tristan Bourcier; Ermanno Candolfi
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

5.  Molecular characterization of Drosophila cells persistently infected with Flock House virus.

Authors:  Juan Jovel; Anette Schneemann
Journal:  Virology       Date:  2011-08-26       Impact factor: 3.616

6.  Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.

Authors:  Bernard J C Macatangay; Lu Zheng; Charles R Rinaldo; Alan L Landay; Richard B Pollard; Savita Pahwa; Michael M Lederman; R Pat Bucy
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

7.  A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector.

Authors:  W Zhang; T Zhang; M-J Turk; E J Usherwood
Journal:  Cancer Immunol Immunother       Date:  2010-05       Impact factor: 6.968

8.  Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Molly R Perkins; Caroline Ryschkewitsch; Julia C Liebner; Maria Chiara G Monaco; Danielle Himelfarb; Sara Ireland; Annelys Roque; Heather L Edward; Peter N Jensen; Gina Remington; Thomas Abraham; Jaspreet Abraham; Benjamin Greenberg; Charles Kaufman; Chris LaGanke; Nancy L Monson; Xiaoning Xu; Elliot Frohman; Eugene O Major; Daniel C Douek
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

9.  Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.

Authors:  Jiang Li; Qiu-yan Chen; Haoyuan Mo; Yi-lan Zhang; Zhou-feng Huang; Yi-xin Zeng
Journal:  Int J Biol Sci       Date:  2011-05-18       Impact factor: 6.580

10.  Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Authors:  Joseph E Blaney; Andrea Marzi; Mallory Willet; Amy B Papaneri; Christoph Wirblich; Friederike Feldmann; Michael Holbrook; Peter Jahrling; Heinz Feldmann; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.